Related references
Note: Only part of the references are listed.First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
Alessandra Larocca et al.
HAEMATOLOGICA (2020)
Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis
Karthik Ramasamy et al.
LEUKEMIA & LYMPHOMA (2020)
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos et al.
LANCET (2020)
Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years
Angelo Belotti et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Network meta-analysis of first-line treatments in transplant-ineligible multiple myeloma patients
Manuel David Gil-Sierra et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
Brian G. M. Durie et al.
BLOOD CANCER JOURNAL (2020)
Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis
Smith Giri et al.
JOURNAL OF GERIATRIC ONCOLOGY (2020)
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji K. Kumar et al.
LANCET ONCOLOGY (2020)
Multiple Myeloma, Version 3.2021
Shaji K. Kumar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis
Yaohua Cao et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials
Leo Sekine et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis
Wenjun Xu et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis
Hedwig M. Blommestein et al.
HAEMATOLOGICA (2019)
Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal
David M. Phillippo et al.
MEDICAL DECISION MAKING (2018)
Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison
Jesus F. San-Miguel et al.
BLOOD (2018)
Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma
Chrissy H. Y. van Beurden-Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Network meta-analysis: application and practice using Stata
Sungryul Shim et al.
EPIDEMIOLOGY AND HEALTH (2017)
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients
Cirino Botta et al.
BLOOD ADVANCES (2017)
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma
Sonja Zweegman et al.
BLOOD (2016)
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma
A. Keith Stewart et al.
BLOOD (2015)
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Evidence Synthesis for Decision Making 1: Introduction
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
Meral Beksac et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
How to obtain the confidence interval from a P value
Douglas G. Altman et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
Anders Waage et al.
BLOOD (2010)
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
Pierre Wijermans et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo et al.
BLOOD (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
